https://www.pharmaradar360.com/article/cd88c9e34d444cb7PharmaRadar360en2026-04-15T10:57:09.000ZDecision: Medical devices given exceptional use authorisationshttps://www.pharmaradar360.com/article/22916c69ddcb62e8PharmaRadar360en2026-04-15T10:46:52.000ZΑνάκληση της παρτίδας EM1425 του καλλυντικού προϊόντος NEPTUNE AFTER SHAVEhttps://www.pharmaradar360.com/article/c13d21eecd4f9822PharmaRadar360en2026-04-15T10:41:52.000ZΑνάκληση της παρτίδας 333570 του συμπληρώματος διατροφής HEALTHAID HAEMOVIT, Liquid Gold Blackcurrant tastehttps://www.pharmaradar360.com/article/8adbe0eeac6882d5PharmaRadar360en2026-04-15T09:31:56.000ZReunión del Comité de Medicamentos Veterinarios de abril de 2026https://www.pharmaradar360.com/article/a252e6f707f9070aPharmaRadar360en2026-04-15T08:21:55.000ZDecision: Orphan registered medicinal productshttps://www.pharmaradar360.com/article/31f76bf56ff05826PharmaRadar360en2026-04-15T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/8127c6d009a911c1PharmaRadar360en2026-04-15T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/0e74cdcb4c228127PharmaRadar360en2026-04-15T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/b11316e69d5068b6PharmaRadar360en2026-04-15T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/5b7e51d8a02bf914PharmaRadar360en2026-04-15T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/b019d5baf8113894PharmaRadar360en2026-04-15T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/7b1622ec12f6c19dPharmaRadar360en2026-04-15T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/8563dbec3a344055PharmaRadar360en2026-04-15T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/b00a8d55b5bb73d8PharmaRadar360en2026-04-15T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/8c8fef13197f208ePharmaRadar360en2026-04-15T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/9c5682c7b021a14ePharmaRadar360en2026-04-15T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/f922446b9fcd3217PharmaRadar360en2026-04-15T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/ac4efc9e8ef1b3e7PharmaRadar360en2026-04-15T00:00:00.000Z6203https://www.pharmaradar360.com/article/7e6a26ec547d9699PharmaRadar360en2026-04-15T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/2a1c3126fffbac79PharmaRadar360en2026-04-14T23:30:00.000ZAstellas Doses First Patient in Phase 3 Study of setidegrasib (ASP3082) for KRAS G12D-mutated Metastatic Pancreatic Ductal Adenocarcinomahttps://www.pharmaradar360.com/article/93bb111e92c90a19PharmaRadar360en2026-04-14T21:49:37.000ZManaging Financial Risk at Site Level: Practical Strategies for Underfunded Studieshttps://www.pharmaradar360.com/article/f41d9ba053287168PharmaRadar360en2026-04-14T19:40:28.000ZThe Need for Clinical Research Sites to Transition to e-Regulatory Binders: Strategies, Pros, and Conshttps://www.pharmaradar360.com/article/8c00b29d0dc2078dPharmaRadar360en2026-04-14T19:39:59.000ZMeasuring Quality in the Age of AI: Why Regulatory Writing Needs a True Standardhttps://www.pharmaradar360.com/article/6a21ebd953e1aae1PharmaRadar360en2026-04-14T19:39:40.000ZEnhancing the Quality of Investigator-Initiated Trials Through Self-Study Moduleshttps://www.pharmaradar360.com/article/e61531582dc9971cPharmaRadar360en2026-04-14T19:39:11.000ZFrom Mapping Your Pathway to Traversing a Careerhttps://www.pharmaradar360.com/article/3e563006e0e75ea0PharmaRadar360en2026-04-14T19:38:47.000ZEmpowering Research-Naïve PIs for Complex and Advanced Therapeutic Trialshttps://www.pharmaradar360.com/article/a85065fe263b3bf3PharmaRadar360en2026-04-14T19:38:16.000ZThe Cost of Turnover in Clinical Operations: What Leaders Can Actually Do About Ithttps://www.pharmaradar360.com/article/2f015ef3d0b39a99PharmaRadar360en2026-04-14T19:37:56.000ZUsing AI to Unlock New Opportunities in Clinical Data Recruitment and Talent Developmenthttps://www.pharmaradar360.com/article/7ba7f079a8964dc6PharmaRadar360en2026-04-14T19:37:37.000ZA Practical Guide to Patient-Centric Trials Using Net Treatment Benefithttps://www.pharmaradar360.com/article/d05125a648bc87afPharmaRadar360en2026-04-14T19:37:18.000ZThe Recurring Conundrum of Diversity: Targeted Precision as an Economically Calculable Strategyhttps://www.pharmaradar360.com/article/f2dd91250352ddecPharmaRadar360en2026-04-14T17:53:12.000ZTransplanting Islet Cells with Piotr Witkowski, MD, PhDhttps://www.pharmaradar360.com/article/265257b2c40e22cbPharmaRadar360en2026-04-14T17:52:37.000ZIn Vivo’s 2026 Rising Leadershttps://www.pharmaradar360.com/article/c0edbb5d2743366ePharmaRadar360en2026-04-14T17:14:20.000ZGuidance: Declaration of Helsinki and Clinical Trial Regulations alignmenthttps://www.pharmaradar360.com/article/f020f20519c1b628PharmaRadar360en2026-04-14T17:13:56.000ZGuidance: Archiving and retention of clinical trial recordshttps://www.pharmaradar360.com/article/be836ce38eeb605dPharmaRadar360en2026-04-14T15:56:27.000ZSELLAS Life Sciences - Clinical Biopharmaceutical Companyhttps://www.pharmaradar360.com/article/70c81a26ccd48450PharmaRadar360en2026-04-14T14:00:41.000ZInterfarma no HBR Summit Brasil: painel debate cuidado baseado em valor como eixo para inovação e sustentabilidadehttps://www.pharmaradar360.com/article/f3cf5fe2308c83ecPharmaRadar360en2026-04-14T13:41:02.000ZInterfarma no HBR Summit Brasil: cuidado baseado em valor é caminho para mais eficiência e melhores desfechos em saúdehttps://www.pharmaradar360.com/article/febb72a16f92c72aPharmaRadar360en2026-04-14T13:38:04.000ZUpdate on Construction of New Plasma-Derived Therapies Manufacturing Facility in Juso, Osaka | Takeda Pharmaceuticalshttps://www.pharmaradar360.com/article/49596db5be21d02fPharmaRadar360en2026-04-14T13:38:04.000Z20,000+ Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 countries | Takeda Pharmaceuticalshttps://www.pharmaradar360.com/article/4c473af8e0fbba70PharmaRadar360en2026-04-14T13:38:04.000ZTakeda Announces Completion of Acquisition of Own Shares | Takeda Pharmaceuticalshttps://www.pharmaradar360.com/article/b3df3da3141e2541PharmaRadar360en2026-04-14T13:38:04.000ZGAMMAGARD LIQUID ERC Approved for Primary Immunodeficiencyhttps://www.pharmaradar360.com/article/0822375a17c0bd15PharmaRadar360en2026-04-14T13:38:04.000ZFiling of Corporate Governance Report to the Tokyo Stock Exchange | Takeda Pharmaceuticalshttps://www.pharmaradar360.com/article/9d01a338763f48f6PharmaRadar360en2026-04-14T13:38:04.000ZTakeda Announces the Pricing Terms of the Previously Announced Cash Tender Offers for Certain Outstanding Notes | Takedahttps://www.pharmaradar360.com/article/93cdc620ada882fbPharmaRadar360en2026-04-14T13:38:04.000ZTakeda Announces New Assignments of Directorshttps://www.pharmaradar360.com/article/fc204f1fc516c285PharmaRadar360en2026-04-14T13:37:57.000ZStatement on Inadvertent Abstract Disclosure for Oveporexton (TAK-861) by World Sleep Congresshttps://www.pharmaradar360.com/article/19683ea67614dfecPharmaRadar360en2026-04-14T13:37:57.000ZTakeda Reports Third-Quarter FY2025 Results | Takeda Pharmaceuticalshttps://www.pharmaradar360.com/article/be921822b3782fa3PharmaRadar360en2026-04-14T13:37:57.000ZTakeda Phase 3 Study Results in Pediatric Ulcerative Colitishttps://www.pharmaradar360.com/article/bcdf75694a45a3b2PharmaRadar360en2026-04-14T13:37:57.000ZRusfertides Phase 3 Trial for Polycythemia Vera at ASCO 2025https://www.pharmaradar360.com/article/e4636f949c687c8bPharmaRadar360en2026-04-14T13:37:57.000ZTakeda Presents Long-Term Data from ADVANCE-CIDP 3 Trial of HYQVIAhttps://www.pharmaradar360.com/article/f48c3647ab28f713PharmaRadar360en2026-04-14T13:37:57.000ZTakeda to Hold Third Quarter FY2022 Earnings Call on February 2https://www.pharmaradar360.com/article/9f590c223b59a084PharmaRadar360en2026-04-14T13:37:57.000ZTakeda Receives Approval to Manufacture and Market Entyvio® Subcutaneous Injection in Japan for the Maintenance Treatment of Moderate to Severe Ulcerative Colitishttps://www.pharmaradar360.com/article/f70640ce922ee02ePharmaRadar360en2026-04-14T13:37:44.000ZNotice Concerning Withdrawal of Shelf Registration Statement and Filing of New Shelf Registration Statement in Japanhttps://www.pharmaradar360.com/article/e6fc351dbf599bfbPharmaRadar360en2026-04-14T13:37:44.000ZADZYNMA® Receives European Commission Approval as First Recombinant ADAMTS13 Therapy for cTTPhttps://www.pharmaradar360.com/article/135d7003c473d4e8PharmaRadar360en2026-04-14T13:37:44.000ZU.S. FDA Approves Takeda’s TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Olderhttps://www.pharmaradar360.com/article/7cdad0f9bfe50a36PharmaRadar360en2026-04-14T13:37:44.000ZTakeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitorhttps://www.pharmaradar360.com/article/010103043cccafaaPharmaRadar360en2026-04-14T13:37:44.000ZTakeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiaryhttps://www.pharmaradar360.com/article/15ea49aded7a9ddaPharmaRadar360en2026-04-14T13:37:44.000ZFDA Accepts Takeda’s Entyvio BLAhttps://www.pharmaradar360.com/article/b68e3e4bab369ce0PharmaRadar360en2026-04-14T12:50:00.000ZErin Lichy Gets Real About Her Natrelle® Breast Augmentationhttps://www.pharmaradar360.com/article/18e767ebbf341be6PharmaRadar360en2026-04-14T12:33:03.000ZNuevos proyecto de consulta para la opinión públicahttps://www.pharmaradar360.com/article/45a66b8315871e3dPharmaRadar360en2026-04-14T12:00:00.000ZCommunity Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinicshttps://www.pharmaradar360.com/article/9ac778cddbd84a41PharmaRadar360en2026-04-14T12:00:00.000ZAmneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.https://www.pharmaradar360.com/article/0e8229e036e90c55PharmaRadar360en2026-04-14T11:00:00.000ZTiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congresshttps://www.pharmaradar360.com/article/67d722a77e2f284dPharmaRadar360en2026-04-14T10:47:33.000ZDecision: Parallel import licences granted in 2026https://www.pharmaradar360.com/article/15882150685c46cePharmaRadar360en2026-04-14T10:45:23.000ZAvacta CEO Christina Coughlin Named as One of In Vivo’s 2026 Rising Leadershttps://www.pharmaradar360.com/article/cb37dc9f36352675PharmaRadar360en2026-04-14T10:07:42.000ZMedicines: Get integrated scientific advice from the MHRA and NICEhttps://www.pharmaradar360.com/article/aba390c444060812PharmaRadar360en2026-04-14T03:00:00.000Z[ANZEN]MHLW Pharmaceuticals and Medical Devices Safety Information No.428 postedhttps://www.pharmaradar360.com/article/c3a81933f934f01aPharmaRadar360en2026-04-14T03:00:00.000Z[SHINSA]The information of New Drug Review with Electronic Data updatedhttps://www.pharmaradar360.com/article/853ebb17588ca640PharmaRadar360en2026-04-14T00:00:00.000ZBausch Health's Dermatology Business, Ortho Dermatologics, Announces the Launch of Biafine®, an Iconic French Skincare Product, Through Convenient Online Ordering